theMednetRegister

Pediatric Hematology/Oncology

Non-Hodgkin Lymphoma   

Questions discussed in this category

Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?
1 Answer available
For pediatric patients with localized diffuse large B-cell lymphoma being treated per COG ANHL 1131 in group B, do you feel it is necessary to complete all lumbar punctures with IT therapy?
2 Answers available
Based on recently published data from COG ANHL12P1, how will you use crizotinib in pediatric and AYA patients with ALK+ anaplastic large cell lymphoma?
How would the risk of VTE associated with crizotinib affect your decision? Should we consider using crizotinib in combination with brentuximab?
3 Answers available
Does R-CHOP provide durable remission in low-risk pediatric Burkitt or Burkitt-like lymphoma?
2 Answers available
When is a lumbar puncture indicated in a lymphoma staging work up for a pediatric or AYA patient?
Is an LP only recommended in the setting of particular subtypes of lymphoma or symptoms of CNS disease?
1 Answer available
What is the role of upfront addition of an ALK inhibitor in an ALK positive mature B Cell lymphoma in an AYA patient?
1 Answer available
What is the preferred regimen for AYA patients with T-Cell Lymphoblastic Lymphoma?
1 Answer available
How is pediatric and young adult primary bone lymphoma risk stratified?
NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...
1 Answer available
Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?
1 Answer available
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
3 Answers available
What is your approach for salvage therapy in a patient with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma that has received a Rituximab-containing upfront regimen?
1 Answer available
How would you treat an adolescent or young adult with newly diagnosed hepatosplenic T-cell lymphoma?
1 Answer available
Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?
What if the patient has a history of confirmed COVID-19 but has since recovered?
1 Answer available


Papers discussed in this category

J Clin Oncol, 2019 Oct 14
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Blood, 2021 Mar 08
Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with ALK+ALCL: Results of COG Trial ANHL12P1.
Cancer chemotherapy and pharmacology, 2017-01
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.
British journal of haematology, 2008-06
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
Leukemia, 2021 May 03
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
N Engl J Med,
Treatment of children and young adults with early-stage non-Hodgkin's lymphoma.
J Clin Oncol, 2022 Dec 19
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
N Engl J Med,
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

Related Topics in Pediatric Hematology/Oncology

Copyright © 2024 theMednet
All Rights Reserved.